The FDA publishes a substantial amount of what is about to happen in this industry, and almost nobody in business development reads it as anything other than news.
Regulatory events are the most predictable signals in life sciences
Unlike funding rounds and acquisitions, which arrive without warning, much of the regulatory calendar is known in advance. PDUFA dates are set. Advisory committee meetings are scheduled. Designations are announced. Filings are disclosed.
This is a rare gift: a buying signal you can see coming months ahead, which means you can be early rather than fast.
What each event actually predicts
- An approaching PDUFA date means a company is building commercially right now: hiring a launch team, engaging agencies, sorting market access, scaling manufacturing. All of that is decided before the date, not after.
- Breakthrough or priority review designation compresses the timeline, meaning the company must move faster commercially than they planned, and is likely under-resourced for it.
- A filing acceptance starts the clock formally and makes the launch real inside the company.
- An approval means the launch is happening now, and the post-marketing commitments, Phase 4 studies, and registry work begin.
- A complete response letter is the signal nobody watches: the company needs additional work, often more trials or manufacturing remediation, and needs it urgently.
The rejection nobody calls about
That last one deserves attention. When a company receives a complete response letter, they have a problem, a deadline, and often a gap in capability. They need regulatory expertise, possibly additional clinical work, sometimes manufacturing remediation.
Every competitor is quietly writing the company off. Almost nobody calls to help. It is one of the most open doors in the industry, and it stays open only briefly.
Working the calendar
The discipline is simple: look at what is scheduled, work backward to when the associated buying decision gets made, and be in front of the company at that point rather than reacting to the announcement.
If you are calling on the day of the approval, you are talking to a company whose vendors were selected six months ago, in a decision you could have seen coming.
Know who to call
Half of next year’s launches are already on the calendar, and the vendor decisions are being made now.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
How can the FDA calendar be used for sales?
Because much of it is public and known in advance. PDUFA dates are set, advisory committee meetings are scheduled, and designations are announced, which makes regulatory events a rare buying signal you can see coming months ahead. The discipline is to work backward from the scheduled date to when the buying decision is made.
What does an approaching PDUFA date signal?
That the company is building commercially right now: hiring a launch team, engaging agencies, sorting market access and scaling manufacturing. All of those decisions happen before the PDUFA date, not after, so a vendor calling on approval day is talking to a company whose vendors were chosen months earlier.
What is the most overlooked regulatory signal?
The complete response letter. When a company is rejected they have an urgent problem, a deadline, and often a capability gap, needing regulatory expertise, additional clinical work or manufacturing remediation. Competitors quietly write the company off and almost nobody calls to help, making it one of the most open doors in the industry.
